My research examines mechanisms of vascular dysfunction in humans with traditional and non-traditional cardiovascular disease risk. I have developed a model to examine microvascular dysfunction mechanisms in humans, which allows pharmaco dissection that was previously impossible. We have explored several molecular targets, mediating vascular dysfunction, translating preclinical research to humans using this novel bioassay.
One of the current challenges in experiments is that vasodilator and vasoconstrictor responses are caused by multiple mechanisms. To isolate the mechanisms of interest, pharmacological agents must be used. While this approach is limited, it does allow for a more comprehensive understanding of cutaneous vascular responses.
In clinical cohorts such as hypertension and major depressive disorder, or MDD, we have discovered microvascular dysfunction. The possible reasons for this dysfunction in these groups are increased arginase and reactive oxygen species activity, respectively. Short-term salicylate treatment has been found to be effective in improving microvascular function and MDD.
This technique is minimally invasive and allows for well controlled pharmacological dissection of the mechanisms of function of a local vascular bed. This is opposed to techniques like postocclusive reactive hyperemia and iontophoresis, which are useful, but allow for a little control of a pharmacologic tool. Our laboratory is currently investigating the contribution of inflammation and mediating microvascular dysfunction in women with endometriosis.
In addition, we plan to investigate similar mechanisms in non-Hispanic black women.
